SGLT2 Inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-021-00495-5
Abstract: Sodium–glucose co-transporter 2 inhibitors (SGLT2i) were developed as oral hypoglycemic agents to control hyperglycemia in patients with type 2 diabetes mellitus (T2DM), but the results of several large randomized controlled trials over the past decade… read more here.
Keywords: sglt2 inhibitors; inhibitors dawn; cardio; new era ... See more keywords